Status Epilepticus – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Status Epilepticus – Drugs In Development, 2024 report and make more profitable business decisions.
Status epilepticus is an emergency neurological condition where seizures last for more than five minutes; historically, it was diagnosed for seizures longer than than 30 minutes. Patients with this condition do not regain consciousness between seizures, which can lead to death. Hence, it requires immediate emergency evaluation and management. Seizures can be convulsive or non-convulsive, and are most commonly observed in pediatric patients as febrile seizures. It can be caused by pre-existing seizures in patients on irregular medications, age, hypoxia, drug toxicity, genetics, head trauma, or CNS infections like meningitis. Neuroimaging studies and laboratory investigations are done for the diagnosis. CT scan, EEG, and MRI are the most common procedures. Management is primarily to abort the seizures by using emergency or rescue medications, providing supportive care with oxygen therapy, and anti-epileptic drugs.
The Status Epilepticus drugs in development market research report provide comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Status Epilepticus | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Status Epilepticus therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Status Epilepticus pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Status Epilepticus treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aculys Pharma LLCBio-Pharm Solutions Co Ltd
Crossject SA
Jazz Pharmaceuticals Plc
Marinus Pharmaceuticals Inc
Neumirna Therapeutics ApS
Neuraxpharm France SAS
Ovid Therapeutics Inc
Pfizer Inc
PharmaTher Holdings Ltd
PrevEp Inc
SciSparc Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Status Epilepticus reports